News
12-07-2012, 10:20 AM
Results from the first large, global Phase III study of Halaven (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
More... (http://www.news-medical.net/news/20121207/Results-of-Halaven-Phase-III-study-in-metastatic-breast-cancer-presented-at-2012-CTRC-AACR-SABCS.aspx)
More... (http://www.news-medical.net/news/20121207/Results-of-Halaven-Phase-III-study-in-metastatic-breast-cancer-presented-at-2012-CTRC-AACR-SABCS.aspx)